Novavax starts enrolling people for phase two of Covid-19 vaccine trial
In the new phase, the age range has been expanded, with adults between 60 and 84 years accounting for nearly 50 percent of the trial's population
File Photo: Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
Novavax Inc said on Monday it has begun enrolling volunteers for the second phase of an ongoing clinical trial of its Covid-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.
In the new phase, the age range has been expanded, with adults between 60 and 84 years accounting for nearly 50 percent of the trial's population.
Early-stage data from a small clinical trial of the vaccine has shown it produced high levels of virus-fighting antibodies, and the company aims to begin larger studies to obtain regulatory approvals as early as December.
Keep updated, follow The Business Standard's Google news channel
